LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website: https://business.uoregon.edu/centers/lce

Clinical Trials

Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

Phase 2

Active, not recruiting

Conditions: Methicillin-resistant Staphylococcus Aureus
Skin Infection

Interventions: Drug: TMP-SMX
Drug: DOXY

First Posted Date: 2018-08-20

Last Posted Date: 2024-12-05

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 462

Registration Number: NCT03637400

Locations: 🇺🇸
Olive View-UCLA Medical Center, Sylmar, California, United States
🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

Inspiratory Muscle Therapy in Subjects With Fontan Circulations

Not Applicable

Completed

Conditions: Single-ventricle

Interventions: Device: Inspiratory muscle therapy

First Posted Date: 2017-11-13

Last Posted Date: 2024-01-29

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 7

Registration Number: NCT03339466

Bandage Contact Lenses for Corneal Abrasions

Phase 2

Conditions: Corneal Abrasion
Eye Trauma

Interventions: Drug: Eyedrop
Device: Bandage contact lens
Drug: Hydrocodone

First Posted Date: 2017-07-02

Last Posted Date: 2018-02-01

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 60

Registration Number: NCT03206723

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

Adrenal Cortical Function and Vitamin A Deficiency in Sepsis

Phase 4

Completed

Conditions: Sepsis

Interventions: Drug: Solumedrol 20mg
Drug: Vitamin A 100,000 IU
Other: Placebo

First Posted Date: 2017-05-15

Last Posted Date: 2017-05-16

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 300

Registration Number: NCT03152474

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Phase 1

Active, not recruiting

Conditions: Mucopolysaccharidosis VI
Mucopolysaccharidosis I
Mucopolysaccharidosis II

Interventions: Drug: Adalimumab Injection [Humira]
Drug: Saline Solution for Injection

First Posted Date: 2017-05-15

Last Posted Date: 2024-10-22

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 14

Registration Number: NCT03153319

Locations: 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Hormonal Mechanisms of Sleep Restriction - Axis Study

Phase 1

Active, not recruiting

Conditions: Sleep Restriction

Interventions: Drug: Gonadorelin
Drug: Ganirelix
Drug: Ketoconazole Pill
Drug: Dexamethasone Injection
Drug: Corticorelin
Drug: Hydrocortisone Injection
Drug: Dexamethasone
Drug: Placebo oral capsule
Drug: Cosyntropin Injectable Product
Drug: Saline Solution
Drug: Recombinant Human Luteinizing Hormone
Drug: Saline Solution for Injection

First Posted Date: 2017-05-08

Last Posted Date: 2024-04-23

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT03142893

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

Not Applicable

Conditions: Overactive Bladder

Interventions: Other: PTNS maintenance

First Posted Date: 2017-05-02

Last Posted Date: 2017-05-02

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 70

Registration Number: NCT03136601

Locations: 🇺🇸
Harbor UCLA Medical Center, Torrance, California, United States

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Glycopyrrolate / Formoterol

First Posted Date: 2017-03-16

Last Posted Date: 2022-02-17

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 52

Registration Number: NCT03081156

Locations: 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

Phase 2

Completed

Conditions: Bone and Joint Infection

Interventions: Drug: Tedizolid

First Posted Date: 2017-01-04

Last Posted Date: 2023-12-13

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 44

Registration Number: NCT03009045

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Los Angeles BioMedical Research Institute (LA BioMed), Torrance, California, United States

Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy

Phase 4

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: placebo
Drug: Vascepa

First Posted Date: 2016-10-06

Last Posted Date: 2023-02-21

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT02926027

Locations: 🇺🇸
Intermountain Medical Center, Intermountain Heart Institute, Murray, Utah, United States
🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy